Experimental Drug Cuts Stroke Risk In Patients With Atrial Fibrillation

A new research discovered a drug that cuts stroke risk by three times in patients with irregular heartbeats, when compared with other popular drugs.

According to research presented at European Society of Cardiology meeting in Barcelona, people taking dabigatran etexilate, made by German pharmaceutical Boehringer Ingelheim were also at risk to have heart attacks or other side-effects like stomach pain.

Warfarin, which has been around since 1950s, has certain side effects like bleeding risks and requires lifestyle changes like dietary restrictions.

A new research on dabigatran, sold as Pradaxa in 40 countries to prevent blood clots, has found that risk of stroke is reduced even further to about 0.10 percent every year. So, doctors hope that the new drug can help improve treatment for patients with heart diseases.

Source: The Associated Press